Literature DB >> 29114939

Three-dimensional endoscopy for endoscopic salvage nasopharyngectomy: Preliminary report of experience.

Jimmy Yu Wai Chan1, William Ignace Wei1.   

Abstract

BACKGROUND: Prospective, observational study to assess the efficacy of salvage nasopharyngectomy for recurrent nasopharyngeal carcinoma (NPC) via the endoscopic endonasal approach using a three-dimensional (3D) high-definition endoscopic system.
METHODS: Between 2016 and 2017, 30 patients with recurrent NPC were recruited. Patient demographics, tumor characteristics, and perioperative data were recorded. Instrument ergonomics and perceived advantages were assessed by the operating, assisting, and observing surgeons.
RESULTS: The majority (70%) of patients received radiotherapy alone as the initial treatment for NPC, and tumor recurred after a mean interval of 16.8 months. The tumor (T) classifications of the recurrent (R) tumors were: RT1: 46.7%; RT2: 33.3%; and RT3: 20.0%. The mean operative time was 293.3 minutes, and no conversion to open approach was necessary. Internal carotid artery dissection was required in nine patients, and the resection and repair of dura was required in six patients. The most common method of reconstruction was free vastus lateralis flap (46.7%). Microscopically clear resection margins were achieved in 73.3% of patients. The mean hospital stay was 6.8 days. There was no hospital mortality. One patient developed minor secondary hemorrhage, whereas the other developed transient contralateral vocal cord paralysis. On quantitative assessment, surgeons noticed a significant advantage of the 3D system with regard to depth and size perception, anatomy identification, and hand-eye coordination, whereas there was no significant difference in terms of strain sensation and dizziness.
CONCLUSION: The 3D high-definition endoscopic system improves the precision of endoscopic nasopharyngectomy, particularly when dissection of the internal carotid artery and dura is required. LEVEL OF EVIDENCE: 4. Laryngoscope, 128:1386-1391, 2018.
© 2017 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  3D endoscopy; Recurrent nasopharyngeal carcinoma; endoscopic endonasal nasopharyngectomy; internal carotid artery; skull base

Mesh:

Year:  2017        PMID: 29114939     DOI: 10.1002/lary.26993

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  6 in total

1.  Novel three-dimensional image system for endoscopic ear surgery.

Authors:  Chin-Kuo Chen; Li-Chun Hsieh; Tsun-Hao Hsu
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-10-01       Impact factor: 2.503

Review 2.  Recommendations for surgical management of recurrent nasopharyngeal carcinoma during COVID-19 pandemic.

Authors:  Velda Ling Yu Chow; Jimmy Yu Wai Chan; Stanley Thian Sze Wong; William Ignace Wei
Journal:  Laryngoscope Investig Otolaryngol       Date:  2020-06-13

Review 3.  Recent advances in the management of nasopharyngeal carcinoma.

Authors:  W K Jacky Lam; Jason Y K Chan
Journal:  F1000Res       Date:  2018-11-21

4.  Clinical characteristics and prognostic value of pre-retreatment plasma epstein-barr virus DNA in locoregional recurrent nasopharyngeal carcinoma.

Authors:  Ming-Zhu Liu; Shuo-Gui Fang; Wei Huang; Han-Yu Wang; Yun-Ming Tian; Run-Da Huang; Zhuang Sun; Chong Zhao; Tai-Xiang Lu; Ying Huang; Fei Han
Journal:  Cancer Med       Date:  2019-07-03       Impact factor: 4.452

Review 5.  Recurrent Nasopharyngeal Cancer: Critical Review of Local Treatment Options Including Recommendations during the COVID-19 Pandemic.

Authors:  Michaela Svajdova; Marian Sicak; Pavol Dubinsky; Marek Slavik; Pavel Slampa; Tomas Kazda
Journal:  Cancers (Basel)       Date:  2020-11-25       Impact factor: 6.639

Review 6.  Treatment of Recurrent Nasopharyngeal Carcinoma: A Sequential Challenge.

Authors:  Zhouying Peng; Yumin Wang; Ruohao Fan; Kelei Gao; Shumin Xie; Fengjun Wang; Junyi Zhang; Hua Zhang; Yuxiang He; Zhihai Xie; Weihong Jiang
Journal:  Cancers (Basel)       Date:  2022-08-25       Impact factor: 6.575

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.